Form 4: Gilead Sciences' Chief Medical Officer, Merdad Parsey, Reports Changes in Beneficial Ownership

Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports transactions involving common stock and restricted stock units, including acquisitions, disposals, and vesting.

Summary

• On March 10, 2024, Merdad Parsey, the Chief Medical Officer of Gilead Sciences, reported changes in beneficial ownership of Gilead Sciences' securities.
• The transactions included the vesting of 3,455 and 6,946 restricted stock units, which converted into common stock.
• Parsey also acquired 89,660 non-qualified stock options with an exercise price of $75.12, exercisable starting March 10, 2024, and expiring on March 10, 2034.
• Additionally, Parsey acquired 17,640 restricted stock units.
• Following the reported transactions, Parsey directly owns 98,304 shares of common stock, 30,574 restricted stock units from one grant, 48,214 restricted stock units from another grant and 89,660 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive. There's no inherent positive or negative implication for the company's performance.

Positives

• The acquisition of stock options and restricted stock units by a key executive could be interpreted as a positive sign of confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the restricted stock units and stock options suggest a continued relationship between the executive and the company over the next four years.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry. It reflects standard practices for incentivizing and retaining key personnel.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used by companies like Pfizer, Merck, and Johnson & Johnson.
• Vesting schedules, such as the four-year vesting described in the document, are standard practice to ensure long-term alignment of executive interests with shareholder value.
• The specific amounts and terms of the grants would need to be compared against peer companies to determine if they are within industry norms.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they relate to executive compensation and ownership changes.
• Employees may view the executive's stock ownership as a sign of confidence in the company.

Key Dates